Andrew D.C. LaFrence - Mar 30, 2021 Form 4/A - Amendment Insider Report for Vyant Bio, Inc. (VYNT)

Role
Chief Financial Officer
Signature
/s/ Andrew LaFrence
Stock symbol
VYNT
Transactions as of
Mar 30, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
7/13/2021, 09:00 AM
Date Of Original Report
Apr 1, 2021
Next filing
May 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNT Common Stock, $0.0001 par value Other +29.3K 29.3K Mar 30, 2021 Direct F1
transaction VYNT Common Stock, $0.0001 par value Other +26.8K 26.8K Mar 30, 2021 By Trust F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") issued pursuant to the merger on March 30, 2021.

Remarks:

1. Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's Common Stock in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.